Abstract
Much new information has been gleaned about the morphology, biochemistry and function of platelets. The pathophysiology of atherosclerosis and thromboembolic disorders appears to be related to abnormal platelet function. Endothelial damage, thromboxane A2, Thrombin, adenosine diphospate and epinephrine may each promote platelet aggregation, whereas prostacyclin impairs aggregation. Aspirin, sulfinpyrazone and dipyridamole have been used as antiplatelet agents, and specific indications are being developed to guide their selection.
摘要
关于血小板的形态、生物化学和功能，已收集到许多新信息。动脉粥样硬化和血栓栓塞性疾病的病理生理学似乎与血小板功能异常有关。内皮损伤、血栓素A2、凝血酶、二磷酸腺苷和肾上腺素均可促进血小板聚集，而前列环素则抑制聚集。阿司匹林、磺吡酮和双嘧达莫已被用作抗血小板药物，目前正在制定具体的适应证以指导其选择。
相似文献
1
Antiplatelet therapy.抗血小板治疗。
Am Fam Physician. 1981 Oct;24(4):129-34.
2
Aspirin and other platelet-aggregation inhibiting drugs.阿司匹林及其他血小板聚集抑制药物。
Med J Aust. 1985 Jan 7;142(1):41-7.
3
Antiplatelet therapy.
Clin Haematol. 1981 Jun;10(2):497-520.
4
[Current clinical results of antiplatelet medication].
Sangre (Barc). 1984;29(4-C):833-40.
5
Status of antiplatelet drugs in coronary heart disease.
JAMA. 1979 Jun 15;241(24):2649-51.
6
Platelet function inhibitors: their clinical use.
Adv Intern Med. 1978;23:251-64.
7
Antiplatelet agents: rationale and results.
Clin Haematol. 1983 Feb;12(1):311-54.
8
Drugs in the treatment of thrombo-embolic disease--part I.
Ir Med J. 1983 Feb;76(2):101-5, 107.
9
[Prophylactic value of platelet anti-aggregants in coronary disease].
Clin Ter. 1979 Oct 31;91(2):117-27.
10
The role of platelets in thrombotic and vascular disease.
Prog Cardiovasc Dis. 1979 Jul-Aug;22(1):31-52. doi: 10.1016/0033-0620(79)90002-1.
Zotero 插件